Our Journey
2024
Launch and sales start of Cellevat3d® nanofiber microcarriers in gene therapy upstream bioprocessing applications: November 4, BIO-Europe 2024, Stockholm, Sweden.
Cellevate reaches commercial readiness and successfully closes in Q3 the 2nd seed financing round of 3.2 MEUR to support growth and commercialization, with continued support from the strong investor syndicate: Industrifonden, EIC Fund/EIB, Onsight Ventures and existing shareholders.
IP secured in gene therapy and stem cell therapy, production scale up, product validations and evaluations program with leading organizations in gene therapy, QMS/ISO 9001 and production according to GMP ongoing implementation to be finalized in 2025.
Dr. Uwe Gottschalk, world leading bioprocessing leader, appointed as Chairman of Cellevate Board of Directors.
Dr. Bettina Berendsen, top bioprocessing commercial executive, appointed as Board Observer and strategic commercial advisor.
Dr. Christel Fenge, product development and marketing executive strategic expert joins strategic advisory board.
2023
Closing of investment round of 3.6 MEUR for Cellevate scale-up and commercialization of Cellevat3d® nanotechnology in upstream bioprocessing: organization, QMS, ISO 9001, production, development, IP, sales and marketing.
2022
New strategy: Cellevat3d® nanofiber-based upstream bioprocessing solutions.
New CEO, Management Team and Scientific Advisory Board.
Awarded 2.48 MEUR EIC Accelerator grant and 3 MEUR EIC Fund equity investment for commercialization of Cellevat3d® microcarriers.
2017
First Cellevat3d® nanotechnology-based products are customized and sold as R&D Customized Solutions for cell co-culture research applications in neurology, immunology and cancer.
2014
Cellevate is founded as a spinout from NanoLund and Prof. Lars Montelius group.
